Story perspectives

Teva and Royalty Pharma Invest $500M in Vitiligo Drug

1/13/2026

Summary

Story summary

Teva Pharmaceutical Industries and Royalty Pharma will jointly develop an original vitiligo drug, with Royalty Pharma investing $500 million in joint development costs.
Teva's Chief Executive Officer Richard Francis emphasizes strategic collaborations to drive innovation.
Teva projects 2025 revenue near the lower end of its guidance at $16.8–$17 billion.
Teva's market capitalization is about $36.7 billion after a 53% rise in its share price over the past year.

1 of 1

Story summary

Teva Pharmaceutical Industries and Royalty Pharma will jointly develop an original vitiligo drug, with Royalty Pharma investing $500 million in joint development costs.
Teva's Chief Executive Officer Richard Francis emphasizes strategic collaborations to drive innovation.
Teva projects 2025 revenue near the lower end of its guidance at $16.8–$17 billion.
Teva's market capitalization is about $36.7 billion after a 53% rise in its share price over the past year.